将塞来昔布作为帕金森氏病患者的辅助治疗重新利用：一种新的治疗黎明：随机对照试验研究
Repurposing celecoxib as adjuvant therapy in patients with Parkinsonian disease: a new therapeutic dawn: randomized controlled pilot study
影响因子:5.30000
分区:医学3区 / 毒理学2区 免疫学3区
发表日期:2024 Dec
作者:
Mohannad O Khrieba, Sahar K Hegazy, Wessam Mustafa, Sahar M El-Haggar
摘要
帕金森氏病（PD）的临床表现是一种慢性神经退行性疾病，包括胸肌，发球不良，僵硬，静止震颤和姿势不稳定。最近，神经炎症参与PD的发病机理。非甾体类抗炎药的应用引起了人们的注意以治疗这些神经炎症。为了研究Celecoxib在接受常规治疗治疗的PD患者中的可能有效性。满足PD纳入PD纳入PD的患者已纳入了这项随机，前瞻性，前瞻性和受控研究。将患者随机分配为两组（n = 30）；对照组接受了由左旋多巴/碳纤维组成的标准PD处理，塞来昔布组接受了标准的PD治疗加上塞勒克昔布。一名神经科医生在治疗开始时和6个月后评估了每个患者。评估每位患者统一帕金森氏病评级量表（UPDRS）。治疗前后，评估了α-突触核蛋白（α-SYN），肿瘤坏死因子α（TNF-α），类似受体4（TLR-4），核因子红细胞2相关因子2（NRF-2）（NRF-2）和脑源性神经脱生因子（BDNF）的收费。配对和未配对的t检验分别用于评估组内和组之间的统计显着性。塞来昔布组通过未支付的t检验表现出显着且统计降低，如下所示：TLR-4（p = 0.004）（p = 0.004），TNF-α，TNF-α（tnf-α），TNF-α（p = 0.042），以及α-Syn（p = 0.004）（p = 0.004）（p = 0.004）（p = 0.004）（p =0。与对照组相比，NRF-2（p = 0.004）。同样，塞来昔布组的UPDR显着降低（p <0.05）。在管理PD.NCT05962957的患者中，Celecoxib可能是一种有希望的辅助治疗。
Abstract
The clinical presentations of Parkinson's disease (PD), a chronic neurodegenerative condition, include bradykinesia, hypokinesia, stiffness, resting tremor, and postural instability. Recently, neuroinflammation is involved in pathogenesis of PD. Application of nonsteroidal anti-inflammatory drugs captured attention to treat these neuroinflammation.To investigate the possible effectiveness of celecoxib in patients with PD treated with conventional treatment.Sixty outpatients who fulfilled the inclusion requirements for PD were enrolled in this randomized, prospective, and controlled study. The patients were allocated into two groups at random (n = 30); the control group received standard PD treatment, consisting of levodopa/carbidopa, and the celecoxib group received standard PD treatment plus celecoxib. A neurologist evaluated each patient at the beginning of the treatment and after 6 months. Assessment of Unified Parkinson's disease rating scale (UPDRS) for each patient. Before and after treatment, α -synuclein (α-Syn), tumor necrosis factor alpha (TNF-α), Toll like receptors-4 (TLR-4), nuclear factor erythroid 2-related factor 2 (Nrf-2) and brain-derived neurotropic factor (BDNF) were assessed. Paired and unpaired t tests were used to assess statistical significance within and between groups respectively.The celecoxib group exhibited a significant and statistical reduction in the level of measured parameters by unpaired t test as followed: TLR-4 (p = 0.004), TNF-α (p = 0.042), and α-Syn (p = 0.004) apart from a significant increase in BDNF (p = 0.0005) and Nrf-2 (p = 0.004), in comparison with the control group. Also, UPDRS was significantly decreased in celecoxib group (p < 0.05).Celecoxib could be a promising adjuvant therapy in managing patients with PD.NCT05962957.